CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 


Atara Biotherapeutics, Inc.  (ATRA)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

ATRA's Operating Income Growth by Quarter and Year

Atara Biotherapeutics,'s Operating Income results by quarter and year




ATRA Operating Income (in millions $) FY 2018 FY 2017 FY 2016 FY 2015
IV Quarter December - -35.80 -18.75 -21.77
III Quarter September -60.22 -31.66 -25.94 -12.26
II Quarter June -52.62 -27.91 -19.49 -15.11
I Quarter March -42.45 -26.16 -17.06 -9.31
FY   -155.29 -121.53 -81.24 -58.45



ATRA Operating Income third quarter 2018 Y/Y Growth Comment
Atara Biotherapeutics, Inc. in the third quarter recorded Operating Loss of $ -60.22 millions.

According to the results reported in the third quarter, Atara Biotherapeutics, Inc. achieved the best Operating Income growth in Biotechnology & Drugs industry. While Atara Biotherapeutics, Inc.' s Operating Income no change of % ranks overall at the positon no. in the third quarter.

Explain Operating Income growth


ATRA Operating Income ( Y/Y Growth %) 2018
2017 2016 2015
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Atara Biotherapeutics,'s third quarter 2018 Operating Income $ 0.00 millions ATRA's Income Statement
Atara Biotherapeutics,'s third quarter 2017 Operating Income $ 0.00 millions Quarterly ATRA's Income Statement
New: More ATRA's historic Operating Income Growth >>


ATRA Operating Income (Quarter on Quarter Growth %)

2018
2017 2016 2015
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Operating Income third quarter 2018 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Operating Income third quarter 2018 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Operating Income by Quarter for the Fiscal Years 2015, 2016, 2017, 2018

Atara Biotherapeutics,'s Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ATRA's III. Quarter Q/Q Operating Income Comment
III. Quarter 2018 Operating Loss of -60.22 millions by Atara Biotherapeutics, Inc. come out even worse considering the -52.62 millions Operating Loss in the second quarter.

Within Biotechnology & Drugs industry Atara Biotherapeutics, Inc. achieved highest sequential Operating Income growth. While Atara Biotherapeutics,'s Operating Income growth quarter on quarter, overall rank is .


Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ATRA's III. Quarter Q/Q Operating Income Comment
Recent accomplishment of -60.22 millions by Atara Biotherapeutics, Inc. look even more unfavourable considering the -52.62 millions a quarter before.

Within Biotechnology & Drugs industry Atara Biotherapeutics, Inc. achieved highest sequential Operating Income growth. While Atara Biotherapeutics,'s Operating Income growth quarter on quarter, overall rank is .


Atara Biotherapeutics,'s 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Sep 30 2018)
12 Months Ending
(Jun 30 2018)
12 Months Ending
(Mar 31 2018)
12 Months Ending
(Dec 31 2017)
12 Months Ending
(Sep 30 2017)
Cumulative Operating Income 12 Months Ending $ -191.10 $ -162.54 $ -137.82 $ -121.53 $ -104.48
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #




Cumulative Operating Income growth Comment
Atara Biotherapeutics, Inc.' has realized cumulative trailing twelve months Operating Loss of $ -191 millions in the Sep 30 2018 period.
The situation is getting worse as the cumulative Operating Loss is getting bigger from $ -162.54 millions in TTM ending quarter Jun 30 2018 and $ -52.62 millions for the twelve months ending in the quarter a year ago.

Atara Biotherapeutics, Inc. achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment
Atara Biotherapeutics, Inc.' has realized cumulative trailing twelve months Operating Loss of $ -191 millions in the Sep 30 2018 period.
The business is worsening as the cumulative Operating Loss is inflating from $ -162.54 millions in TTM ending quarter Jun 30 2018 and $ -52.62 millions for the twelve months ending in the quarter Sep 30 2017.

Atara Biotherapeutics, Inc. achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Operating Income Growth
Biotechnology & Drugs Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
ATRA's Operating Income Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for ATRA's Competitors
Operating Income Growth for Atara Biotherapeutics,'s Suppliers
Operating Income Growth for ATRA's Customers

You may also want to know
ATRA's Annual Growth Rates ATRA's Profitability Ratios ATRA's Asset Turnover Ratio ATRA's Dividend Growth
ATRA's Roe ATRA's Valuation Ratios ATRA's Financial Strength Ratios ATRA's Dividend Payout Ratio
ATRA's Roa ATRA's Inventory Turnover Ratio ATRA's Growth Rates ATRA's Dividend Comparisons



Companies with similar Operating Income no change for the quarter ending Sep 30 2018 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Sep 30 2018
Lilly Eli & Co  135.57 %$ 135.574 millions
Integra Lifesciences Holdings Corp  122.49 %$ 122.486 millions
Jazz Pharmaceuticals Plc  118.36 %$ 118.355 millions
Diffusion Pharmaceuticals Inc.  108.37 %$ 108.369 millions
Incyte Corp  108.04 %$ 108.043 millions
Pro Dex Inc  100.46 %$ 100.464 millions
Integrated Biopharma Inc  91.94 %$ 91.943 millions
Spring Pharmaceutical Group, Inc.  83.14 %$ 83.138 millions
China Senior Living Industry International Holding  74.29 %$ 74.287 millions
Amedisys Inc  70.71 %$ 70.710 millions
Corcept Therapeutics Inc  68.60 %$ 68.605 millions
Supernus Pharmaceuticals Inc  67.73 %$ 67.733 millions
Bristol Myers Squibb Co  67.24 %$ 67.238 millions
Lhc Group, Inc  63.76 %$ 63.760 millions
Natures Sunshine Products Inc  63.09 %$ 63.092 millions
Techcare Corp.  61.91 %$ 61.911 millions
Alpha Pro Tech Ltd  58.65 %$ 58.655 millions
Abiomed Inc  58.61 %$ 58.608 millions
Medpace Holdings, Inc.  56.52 %$ 56.518 millions
Celgene Corp  54.84 %$ 54.839 millions
Exelixis, Inc.  54.20 %$ 54.196 millions
Staar Surgical Co  51.77 %$ 51.774 millions
Radnet, Inc.  51.75 %$ 51.748 millions
Orasure Technologies Inc  48.34 %$ 48.340 millions


     
       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

EACO's Profile

Stock Price

EACO's Financials

Business Description

Fundamentals

Charts & Quotes

EACO's News

Suppliers

EACO's Competitors

Customers & Markets

Economic Indicators

EACO's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Expectations

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2018 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071